Sign Up Today and Learn More About CytoAgents Stock
Invest in or calculate the value of your shares in CytoAgents or other pre-IPO companies through EquityZen's platform.
CytoAgents Stock (CYTA)
CytoAgents is a biotechnology company focused on the the treatment of COVID-19, Influenza, and other viral infectious diseases.
About CytoAgents Stock
Founded
2018
Headquarters
Pittsburgh, PA, US
Industries
Software, Artificial Intelligence, Data and Analytics
CytoAgents Press Mentions
Stay in the know about the latest news on CytoAgents
Opinion: To Broaden Access to CAR Ts, Mitigate Their Side Effects
biospace • Jan 12, 2026
Appointments and advancements for Dec. 18, 2025
bioworld • Dec 19, 2025
CytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific Officer
businesswire • Dec 16, 2025
CytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific Officer
pharmiweb • Dec 16, 2025
CytoAgents to Present New CTO1681 Data at the ESMO Immuno-Oncology Congress 2025
pharmiweb • Dec 09, 2025
CytoAgents Management
Leadership team at CytoAgents
Founder & CEO
Teresa Whalen
Chief Science Officer
Jodi Craigo
Join now and verify your accreditation status to gain access to:
- CytoAgents Current Valuation
- CytoAgents Stock Price
- CytoAgents Management
- Available deals in CytoAgents and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- CytoAgents Cap Table and Funding History by Share Class and Liquidity Preferences
- CytoAgents Revenue and Financials
- CytoAgents Highlights
- CytoAgents Business Model
- CytoAgents Risk Factors
- CytoAgents Research Report from SACRA Research
Trading CytoAgents Stock
How to invest in CytoAgents stock?
Accredited investors can buy pre-IPO stock in companies like CytoAgents through EquityZen funds. These investments are made available by existing CytoAgents shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell CytoAgents stock?
Shareholders can sell their CytoAgents stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
